Iroko is committed to enhancing the value of established pharmaceuticals.

Since our Company’s founding in 2007, we have obtained global marketing rights to the analgesic Indocin® and the antihypertensive Aldomet® . 

We bring new life to these medicines by identifying new populations who can benefit from them. We seek new geographic markets for our products and new indications for their uses through our established commercial network in more than 40 countries around the world.